Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TARS

TARS - Tarsus Pharmaceuticals Inc Stock Price, Fair Value and News

$64.19-3.96 (-5.81%)
Market Closed

62/100

TARS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

TARS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$77.25

Target 3M

$70.48

Target 6M

$72.67

TARS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TARS Price Action

Last 7 days

-9.8%

Last 30 days

-21.7%

Last 90 days

-6.9%

Trailing 12 Months

25.7%

TARS RSI Chart

TARS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TARS Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-33.57

Price/Sales (Trailing)

7.44

EV/EBITDA

-28.19

Price/Free Cashflow

-47.36

TARS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$77.25

Target 3M

$70.48

Target 6M

$72.67

TARS Fundamentals

TARS Revenue

Revenue (TTM)

366.1M

Rev. Growth (Yr)

146.68%

Rev. Growth (Qtr)

15.62%

TARS Earnings

Earnings (TTM)

-81.2M

Earnings Growth (Yr)

46.26%

Earnings Growth (Qtr)

38.13%

TARS Profitability

EBT Margin

-31.56%

Return on Equity

-24.22%

Return on Assets

-15.18%

Free Cashflow Yield

-2.11%

TARS Investor Care

Shares Dilution (1Y)

11.05%

Diluted EPS (TTM)

-2

TARS Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025233.7M295.5M366.1M0
202442.6M83.4M129.6M183.0M
202327.8M12.5M14.4M17.4M
202249.2M41.4M33.6M25.8M
202100057.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Tarsus Pharmaceuticals Inc

TARS
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
 CEO
 WEBSITEtarsusrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES87

Tarsus Pharmaceuticals Inc Frequently Asked Questions

TARS is the stock ticker symbol of Tarsus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Tarsus Pharmaceuticals Inc is 2.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TARS's fair value in chart for subscribers.

The fair value guage provides a quick view whether TARS is over valued or under valued. Whether Tarsus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tarsus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARS.

As of Wed Jan 28 2026, TARS's PE ratio (Price to Earnings) is -33.57 and Price to Sales (PS) ratio is 7.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARS PE ratio will change depending on the future growth rate expectations of investors.